Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11139354 | 0.86 | CYP3A4 (0.42) | — | |
| SCHEMBL18244863 | 0.79 | IDO1 (0.46) | TAAR1IDO1LOXL2MAOBMIF | |
| SCHEMBL18427888 | 0.78 | HRH3 (0.41) | TAAR1MAOBFFAR1GAALMNA | |
| SCHEMBL7128264 | 0.75 | HTT (0.42) | MAOBDAO | |
| SCHEMBL980506 | 0.75 | TAAR1 (0.50) | TAAR1IDO1LOXL2MAOBMIF | |
| SCHEMBL910567 | 0.74 | ESR1 (0.57) | TAAR1IDO1LMNA | |
| SCHEMBL37742 | 0.74 | IDO1 (0.46) | TAAR1IDO1LOXL2MAOBMIF | |
| SCHEMBL3736025 | 0.74 | TAAR1 (0.48) | TAAR1IDO1MAOBPYCR1 | |
| SCHEMBL3633726 | 0.74 | MIF (0.52) | TAAR1IDO1LOXL2MAOBMIF | |
| SCHEMBL8625033 | 0.74 | HRH3 (0.50) | TAAR1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPO-MED INC. (JP) | 2023-10-05 | — | — | US | claimed |
| EP-4190345-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | Epo-Med Inc. (JP) | 2023-06-07 | — | — | EP | claimed |
| CN-116234541-A | Treatment of diseases by EpoR antagonists | EPO医药株式会社 | 2023-06-06 | — | — | CN | claimed |
| CN-113166203-A | Anti-erythropoietin receptor peptides | EPO医药株式会社 | 2021-07-23 | — | — | CN | claimed |
| EP-3851448-A1 | ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE | EPO-Med Inc. (JP) | 2021-07-21 | — | — | EP | claimed |
| WO-2020054813-A1 | ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE | エポメッド株式会社 | 2020-03-19 | — | — | WO | claimed |
| WO-2017013593-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LIMITED (IN) | 2017-01-26 | — | — | WO | claimed |
| EP-2501685-A1 | [1,5]-DIAZOCIN DERIVATIVES | Mellitech (FR) | 2012-09-26 | — | — | EP | claimed |
| WO-2011058193-A1 | [1,5]-DIAZOCIN DERIVATIVES | MELLITECH (FR) | 2011-05-19 | — | — | WO | claimed |
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | claimed |
| EP-0469887-A1 | Acetamide derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | claimed |
| US-5068222-A | Polypeptides for treatment of cancer | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-11-26 | — | — | US | claimed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | claimed |
| EP-0480918-A4 | REDUCED SIZE LHRH ANALOGS. | ABBOTT LAB (US) | 1991-06-04 | — | — | EP | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0315367-A2 | Polypeptides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-10 | — | — | EP | claimed |
| EP-0142146-B1 | OXO-ANALOGS OF MEVINOLIN-LIKE ANTIHYPERCHOLESTEROLEMIC AGENTS | MERCK & CO. INC. (US) | 1988-08-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPOR, PROKR1, HBZ | TAAR1 1902/4885IDO1 4593/4885LOXL2 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.